docetaxel + epirubicin + fluorouracil

This is a combination chemotherapy regimen consisting of three cytotoxic agents—docetaxel, epirubicin, and fluorouracil. Each drug has a distinct mechanism of action targeting rapidly dividing cancer cells. Docetaxel is a taxane that stabilizes microtubules and inhibits cell division; epirubicin is an anthracycline that intercalates DNA and inhibits topoisomerase II; and fluorouracil (5-FU) is an antimetabolite that interferes with DNA synthesis by inhibiting thymidylate synthase. This combination has been studied primarily in the treatment of breast cancer as neoadjuvant or adjuvant therapy for early-stage or locally advanced disease. It may also be considered in other solid tumors where these agents are individually active.

Other names

docetaxelepirubicinfluorouracil